Periodontitis and type II diabetes: A two-way relationship

International Journal of Evidence-Based Healthcare

Volumn 11, Issue 4, 2013, Pages 317-329

  Chee, Brian ^a   Park, Boram ^a   Bartold, P Mark ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Glycaemic control; Periodontal treatment; Periodontitis; Type II diabetes

Indexed keywords

ADIPOCYTOKINE; GLYCOSYLATED HEMOGLOBIN;

EDITORIAL; GLUCOSE BLOOD LEVEL; GLYCAEMIC CONTROL; HUMAN; INFLAMMATION; INSULIN RESISTANCE; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIODONTAL TREATMENT; PERIODONTITIS; PHYSIOLOGY; RISK FACTOR; SEVERITY OF ILLNESS INDEX;

GLYCAEMIC CONTROL; PERIODONTAL TREATMENT; PERIODONTITIS; TYPE II DIABETES;

ADIPOKINES; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INFLAMMATION; INSULIN RESISTANCE; PERIODONTITIS; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 84888875322     PISSN: 17441595     EISSN: 17441609     Source Type: Journal    
DOI: 10.1111/1744-1609.12038     Document Type: Editorial

References (166)

1. Löe H, Theilade E, Jensen SB. Experimental gingivitis in man. J Periodontol 1965; 36: 177-187.
2. Kornman KS. Mapping the pathogenesis of periodontitis: a new look. J Periodontol 2008; 79: 1560-1568.
3. Eke PI, Dye BA, Wei L, Thornton-Evans GO, Genco RJ. Prevalence of periodontitis in adults in the United States: 2009 and 2010. J Dent Res 2012; 91: 914-920.
4. Bourgeois D, Bouchard P, Mattout C. Epidemiology of periodontal status in dentate adults in France, 2002-2003. J Periodontal Res 2007; 42: 219-227.
5. Robert-Thomson K, Do L. Oral health status. In: Slade GD, Spencer AJ, Roberts-Thomson KF, eds. Australia's Dental Generations: The National Survey of Adult Oral Health 2004-06. AIHW cat. no. DEN 165. Canberra: Australian Institute of Health and Welfare, (Dental Statistics and Research Series No. 34), 2007; 118.
6. Genco RJ, Grossi SG, Ho A, Nishimura F, Murayama Y. A proposed model linking inflammation to obesity, diabetes, and periodontal infections. J Periodontol 2005; 76 (11 Suppl.): 2075-2084.
7. Page RC, Eke PI. Case definition for use in population-based surveillance of periodontitis. J Periodontol 2007; 78: 1387-39.
8. Scannapieco FA. Systemic effects of periodontal diseases. Dent Clin North Am 2005; 49: 533-550.
9. Scannapieco FA, Dasanayake AP, Chhun N. Does periodontal therapy reduce the risk for systemic diseases? Dent Clin North Am 2010; 54: 163-181.
10. Chavarry NG, Vettore MV, Sansone C, Sheiham A. The relationship between diabetes mellitus and destructive periodontal disease: a meta-analysis. Oral Health Prev Dent 2009; 7: 107-127.
11. Khader YS, Dauod AS, El-Qaderi SS, Alkafajei A, Batayha WQ. Periodontal status of diabetics compared with nondiabetics: a meta-analysis. J Diabetes Complications 2006; 20: 59-68.
12. Salvi GE, Carollo-Bittel B, Lang NP. Effects of diabetes mellitus on periodontal and peri-implant conditions: update on associations and risks. J Clin Periodontol 2008; 35 (8 Suppl.): 398-409.
13. Mealey BL, Ocampo GL. Diabetes mellitus and periodontal disease. Periodontol 2000 2007; 44: 127-153.
14. Tsai C, Hayes C, Taylor GW. Glycemic control of type 2 diabetes and severe periodontal disease in the US adult population. Community Dent Oral Epidemiol 2002; 30: 182-192.
15. Loe H. Periodontal disease. The sixth complication of diabetes mellitus. Diabetes Care 1993; 16: 329-334.
16. Taylor GW. Bidirectional interrelationships between diabetes and periodontal diseases: an epidemiologic perspective. Ann Periodontol 2001; 6: 99-112.
17. Stumvoll M, Goldstein BJ, van Haeften TW. Type 2 diabetes: principles of pathogenesis and therapy. Lancet 2005; 365: 1333-1346.
18. International Diabetes Federation. Diabetes and impaired glucose tolerance. Global burden: prevalence and projections, 2010 and 2030. 2009. Accessed 31 October 2012. Available from: http://www.diabetesatlas.org/content/diabetes-and-impaired-glucose-tolerance
19. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27: 1047-1053.
20. Nelson RG, Shlossman M, Budding LM etal. Periodontal disease and NIDDM in Pima Indians. Diabetes Care 1990; 13: 836-840.
21. Emrich LJ, Shlossman M, Genco RJ. Periodontal disease in non-insulin-dependent diabetes mellitus. J Periodontol 1991; 62: 123-131.
22. Taylor GW, Burt BA, Becker MP, Genco RJ, Shlossman M. Glycemic control and alveolar bone loss progression in type 2 diabetes. Ann Periodontol 1998; 3: 30-39.
23. Jimenez M, Hu FB, Marino M, Li Y, Joshipura KJ. Type 2 diabetes mellitus and 20 year incidence of periodontitis and tooth loss. Diabetes Res Clin Pract 2012; 98: 494-500.
24. Simpson TC, Needleman I, Wild SH, Moles DR, Mills EJ. Treatment of periodontal disease for glycaemic control in people with diabetes. Cochrane Database Syst Rev 2010; (5): CD004714. doi: 10.1002/14651858.CD004714.pub2.
25. Oliver RC, Tervonen T. Periodontitis and tooth loss: comparing diabetics with the general population. J Am Dent Assoc 1993; 124: 71-76.
26. Seppala B, Seppala M, Ainamo J. A longitudinal study on insulin-dependent diabetes mellitus and periodontal disease. J Clin Periodontol 1993; 20: 161-165.
27. Taylor GW, Burt BA, Becker MP etal. Severe periodontitis and risk for poor glycemic control in patients with non-insulin-dependent diabetes mellitus. J Periodontol 1996; 67 (10 Suppl.): 1085-1093.
28. Tervonen T, Oliver RC. Long-term control of diabetes mellitus and periodontitis. J Clin Periodontol 1993; 20: 431-435.
29. Bacic M, Plancak D, Granic M. CPITN assessment of periodontal disease in diabetic patients. J Periodontol 1988; 59: 816-822.
30. de Pommereau V, Dargent-Pare C, Robert JJ, Brion M. Periodontal status in insulin-dependent diabetic adolescents. J Clin Periodontol 1992; 19: 628-632.
31. Taylor GW, Burt BA, Becker MP etal. Non-insulin dependent diabetes mellitus and alveolar bone loss progression over 2 years. J Periodontol 1998; 69: 76-83.
32. Willershausen-Zonnchen B, Lemmen C, Hamm G. Influence of high glucose concentrations on glycosaminoglycan and collagen synthesis in cultured human gingival fibroblasts. J Clin Periodontol 1991; 18: 190-195.
33. Guzman S, Karima M, Wang HY, Van Dyke TE. Association between interleukin-1 genotype and periodontal disease in a diabetic population. J Periodontol 2003; 74: 1183-1190.
34. Nesse W, Linde A, Abbas F etal. Dose-response relationship between periodontal inflamed surface area and HbA1c in type 2 diabetics. J Clin Periodontol 2009; 36: 295-300.
35. Campos SP, Baumann H. Insulin is a prominent modulator of the cytokine-stimulated expression of acute-phase plasma protein genes. Mol Cell Biol 1992; 12: 1789-1797.
36. Schmidt MI, Duncan BB, Sharrett AR etal. Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities study): a cohort study. Lancet 1999; 353: 1649-1652.
37. Okada H, Murakami S. Cytokine expression in periodontal health and disease. Crit Rev Oral Biol Med 1998; 9: 248-266.
38. Seymour GJ, Gemmell E. Cytokines in periodontal disease: where to from here? Acta Odontol Scand 2001; 59: 167-173.
39. Dunmore SJ, Brown JE. The role of adipokines in beta-cell failure of type 2 diabetes. J Endocrinol 2013; 216: T37-45.
40. Zavalza-Gómez AB, Anaya-Prado R, Rincón-Sánchez AR, Mora-Martínez JM. Adipokines and insulin resistance during pregnancy. Diabetes Res Clin Pract 2008; 80: 8-15.
41. Berg AH, Combs TP, Du X, Brownlee M, Scherer PE. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med 2001; 7: 947-953.
42. Yamauchi T, Kamon J, Waki H etal. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001; 7: 941-946.
43. Xynogala I, Pepelassi E, Perrea D etal. Adiponectin and interleukin-6 levels in insulin-treated diabetic rats with experimental periodontitis. Braz Oral Res 2012; 26: 71-76.
44. Wauters M, Considine RV, Van Gaal LF. Human leptin: from an adipocyte hormone to an endocrine mediator. Eur J Endocrinol 2000; 143: 293-311.
45. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature 1994; 372: 425-432.
46. Zimmet P, Boyko EJ, Collier GR, De Courten M. Etiology of the metabolic syndrome: potential role of insulin resistance, leptin resistance, and other players. Ann N Y Acad Sci 1999; 892: 25-44.
47. Johnson RB, Serio FG. Leptin within healthy and diseased human gingiva. J Periodontol 2001; 72: 1254-1257.
48. Bozkurt FY, Yetkin Ay Z, Sutcu R, Delibas N, Demirel R. Gingival crevicular fluid leptin levels in periodontitis patients with long-term and heavy smoking. J Periodontol 2006; 77: 634-640.
49. Yetkin Ay Z, Kirzioglu FY, Ozturk Tonguc M, Sutcu R, Kapucuoglu N. The gingiva contains leptin and leptin receptor in health and disease. Odontology 2012; 100: 222-231.
50. Karthikeyan BV, Pradeep AR. Leptin levels in gingival crevicular fluid in periodontal health and disease. J Periodontal Res 2007; 42: 300-304.
51. Greenberg AS, McDaniel ML. Identifying the links between obesity, insulin resistance and beta-cell function: potential role of adipocyte-derived cytokines in the pathogenesis of type 2 diabetes. Eur J Clin Invest 2002; 32 (Suppl. 3): 24-34.
52. Pickup JC, Chusney GD, Thomas SM, Burt D. Plasma interleukin-6, tumour necrosis factor alpha and blood cytokine production in type 2 diabetes. Life Sci 2000; 67: 291-300.
53. Dandona P, Aljada A, Bandyopadhyay A. Inflammation: the link between insulin resistance, obesity and diabetes. Trends Immunol 2004; 25: 4-7.
54. Fernandez-Real JM, Ricart W. Insulin resistance and chronic cardiovascular inflammatory syndrome. Endocr Rev 2003; 24: 278-301.
55. Salvi GE, Collins JG, Yalda B, Arnold RR, Lang NP, Offenbacher S. Monocytic TNF alpha secretion patterns in IDDM patients with periodontal diseases. J Clin Periodontol 1997; 24: 8-16.
56. Mohamed-Ali V, Goodrick S, Rawesh A etal. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metab 1997; 82: 4196-4200.
57. Pickup JC, Crook MA. Is type II diabetes mellitus a disease of the innate immune system? Diabetologia 1998; 41: 1241-1248.
58. Pickup JC, Mattock MB, Chusney GD, Burt D. NIDDM as a disease of the innate immune system: association of acute- phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia 1997; 40: 1286-1292.
59. Yudkin JS, Stehouwer CDA, Emeis JJ, Coppack SW. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol 1999; 19: 972-978.
60. Yang Q, Graham TE, Mody N etal. Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature 2005; 436: 356-362.
61. Gavi S, Stuart LM, Kelly P etal. Retinol-binding protein 4 is associated with insulin resistance and body fat distribution in nonobese subjects without type 2 diabetes. J Clin Endocrinol Metab 2007; 92: 1886-1890.
62. Esteve E, Ricart W, Fernandez-Real JM. Adipocytokines and insulin resistance: the possible role of lipocalin-2, retinol binding protein-4, and adiponectin. Diabetes Care 2009; 32 (Suppl. 2): S362-367.
63. Graham TE, Yang Q, Bluher M etal. Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. N Engl J Med 2006; 354: 2552-2563.
64. Young MC, Youn BS, Lee H etal. Plasma retinol-binding protein-4 concentrations are elevated in human subjects with impaired glucose tolerance and type 2 diabetes. Diabetes Care 2006; 29: 2457-2461.
65. Steppan CM, Bailey ST, Bhat S etal. The hormone resistin links obesity to diabetes. Nature 2001; 409: 307-312.
66. Degawa-Yamauchi M, Bovenkerk JE, Juliar BE etal. Serum Resistin (FIZZ3) Protein is increased in obese humans. J Clin Endocrinol Metab 2003; 88: 5452-5455.
67. Yannakoulia M, Yiannakouris N, Bluher S, Matalas AL, Klimis-Zacas D, Mantzoros CS. Body fat mass and macronutrient intake in relation to circulating soluble leptin receptor, free leptin index, adiponectin, and resistin concentrations in healthy humans. J Clin Endocrinol Metab 2003; 88: 1730-1736.
68. Lay SL, Boucher J, Rey A etal. Decreased resistin expression in mice with different sensitivities to a high-fat diet. Biochem Biophys Res Commun 2001; 289: 564-567.
69. Utzschneider KM, Carr DB, Tong J etal. Resistin is not associated with insulin sensitivity or the metabolic syndrome in humans. Diabetologia 2005; 48: 2330-2333.
70. Brown JE, Onyango DJ, Dunmore SJ. Resistin down-regulates insulin receptor expression, and modulates cell viability in rodent pancreatic beta-cells. FEBS Lett 2007; 581: 3273-3276.
71. Retnakaran R, Youn BS, Liu Y etal. Correlation of circulating full-length visfatin (PBEF/NAMPT) with metabolic parameters in subjects with and without diabetes: a cross-sectional study. Clin Endocrinol (Oxf) 2008; 69: 885-893.
72. Fukuhara A, Matsuda M, Nishizawa M etal. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 2005; 307: 426-430.
73. Pradeep AR, Raghavendra NM, Sharma A etal. Association of serum and crevicular visfatin levels in periodontal health and disease with type 2 diabetes mellitus. J Periodontol 2012; 83: 629-634.
74. Lau DC, Dhillon B, Yan H, Szmitko PE, Verma S. Adipokines: molecular links between obesity and atheroslcerosis. Am J Physiol Heart Circ Physiol 2005; 288: H2031-2041.
75. Permutt MA, Wasson J, Cox N. Genetic epidemiology of diabetes. J Clin Invest 2005; 115: 1431-1439.
76. Nesto R. C-reactive protein, its role in inflammation, Type 2 diabetes and cardiovascular disease, and the effects of insulin-sensitizing treatment with thiazolidinediones. Diabet Med 2004; 21: 810-817.
77. Festa A, D'Agostino R, Jr, Howard G, Mykkanen L, Tracy RP, Haffner SM. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000; 102: 42-47.
78. Haffner S, Temprosa M, Crandall J etal. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes 2005; 54: 1566-1572.
79. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001; 286: 327-334.
80. Preshaw PM, Foster N, Taylor JJ. Cross-susceptibility between periodontal disease and type 2 diabetes mellitus: an immunobiological perspective. Periodontol 2000 2007; 45: 138-157.
81. Sun WL, Chen LL, Zhang SZ, Ren YZ, Qin GM. Changes of adiponectin and inflammatory cytokines after periodontal intervention in type 2 diabetes patients with periodontitis. Arch Oral Biol 2010; 55: 970-974.
82. Tennenberg SD, Finkenauer R, Dwivedi A. Absence of lipopolysaccharide-induced inhibition of neutrophil apoptosis in patients with diabetes. Arch Surg 1999; 134: 1229-1233.
83. Preshaw PM, Schifferle RE, Walters JD. Porphyromonas gingivalis lipopolysaccharide delays human polymorphonuclear leukocyte apoptosis in vitro. J Periodontal Res 1999; 34: 197-202.
84. Hart TC, Shapira L, Van Dyke TE. Neutrophil defects as risk factors for periodontal diseases. J Periodontol 1994; 65 (5 Suppl.): 521-529.
85. Van Dyke TE, Vaikuntam J. Neutrophil function and dysfunction in periodontal disease. Curr Opin Periodontol 1994; 19-27.
86. Manouchehr-Pour M, Spagnuolo PJ, Rodman HM, Bissada NF. Impaired neutrophil chemotaxis in diabetic patients with severe periodontitis. J Dent Res 1981; 60: 729-730.
87. Gustke CJ, Stein SH, Hart TC etal. HLA-DR alleles are associated with IDDM, but not with impaired neutrophil chemotaxis in IDDM. J Dent Res 1998; 77: 1497-1503.
88. Graves DT, Liu R, Alikhani M, Al-Mashat H, Trackman PC. Diabetes-enhanced inflammation and apoptosis - impact on periodontal pathology. J Dent Res 2006; 85: 15-21.
89. Glowacka E, Banasik M, Lewkowicz P, Tchorzewski H. The effect of LPS on neutrophils from patients with high risk of type 1 diabetes mellitus in relation to IL-8, IL-10 and IL-12 production and apoptosis in vitro. Scand J Immunol 2002; 55: 210-217.
90. Omori K, Ohira T, Uchida Y etal. Priming of neutrophil oxidative burst in diabetes requires preassembly of the NADPH oxidase. J Leukoc Biol 2008; 84: 292-301.
91. Salvi GE, Yalda B, Collins JG etal. Inflammatory mediator response as a potential risk marker for periodontal diseases in insulin-dependent diabetes mellitus patients. J Periodontol 1997; 68: 127-135.
92. Parfitt AM. The coupling of bone formation to bone resorption: a critical analysis of the concept and of its relevance to the pathogenesis of osteoporosis. Metab Bone Dis Relat Res 1982; 4: 1-6.
93. Liu R, Bal HS, Desta T etal. Diabetes enhances periodontal bone loss through enhanced resorption and diminished bone formation. J Dent Res 2006; 85: 510-514.
94. Redlich K, Smolen JS. Inflammatory bone loss: pathogenesis and therapeutic intervention. Nat Rev Drug Discov 2012; 11: 234-250.
95. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature 2003; 423: 337-342.
96. Caetano-Lopes J, Canhao H, Fonseca JE. Osteoimmunology - the hidden immune regulation of bone. Autoimmun Rev 2009; 8: 250-255.
97. Hofbauer LC, Heufelder AE. Role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in bone cell biology. J Mol Med (Berl) 2001; 79: 243-253.
98. Yasuda H, Shima N, Nakagawa N etal. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci U S A 1998; 95: 3597-3602.
99. Mao D, Epple H, Uthgenannt B, Novack DV, Faccio R. PLCgamma2 regulates osteoclastogenesis via its interaction with ITAM proteins and GAB2. J Clin Invest 2006; 116: 2869-2879.
100. Cochran DL. Inflammation and bone loss in periodontal disease. J Periodontol 2008; 79 (8 Suppl.): 1569-1576.
101. Mahamed DA, Marleau A, Alnaeeli M etal. G(-) anaerobes-reactive CD4+ T-cells trigger RANKL-mediated enhanced alveolar bone loss in diabetic NOD mice. Diabetes 2005; 54: 1477-1486.
102. Liu R, Desta T, He H, Graves DT. Diabetes alters the response to bacteria by enhancing fibroblast apoptosis. Endocrinology 2004; 145: 2997-3003.
103. Al-Mashat HA, Kandru S, Liu R, Behl Y, Desta T, Graves DT. Diabetes enhances mRNA levels of proapoptotic genes and caspase activity, which contribute to impaired healing. Diabetes 2006; 55: 487-495.
104. Liu R, Bal HS, Desta T, Behl Y, Graves DT. Tumor necrosis factor-alpha mediates diabetes-enhanced apoptosis of matrix-producing cells and impairs diabetic healing. Am J Pathol 2006; 168: 757-764.
105. Ohnishi T, Bandow K, Kakimoto K, Machigashira M, Matsuyama T, Matsuguchi T. Oxidative stress causes alveolar bone loss in metabolic syndrome model mice with type 2 diabetes. J Periodontal Res 2009; 44: 43-51.
106. Brownlee M. Lilly lecture 1993. Glycation and diabetic complications. Diabetes 1994; 43: 836-841.
107. Monnier VM, Glomb M, Elgawish A, Sell DR. The mechanism of collagen cross-linking in diabetes: a puzzle nearing resolution. Diabetes 1996; 45 (Suppl. 3): S67-72.
108. Stern D, Yan SD, Yan SF, Schmidt AM. Receptor for advanced glycation endproducts: a multiligand receptor magnifying cell stress in diverse pathologic settings. Adv Drug Deliv Rev 2002; 54: 1615-1625.
109. Lalla E, Lamster IB, Stern DM, Schmidt AM. Receptor for advanced glycation end products, inflammation, and accelerated periodontal disease in diabetes: mechanisms and insights into therapeutic modalities. Ann Periodontol 2001; 6: 113-118.
110. Takeda M, Ojima M, Yoshioka H etal. Relationship of serum advanced glycation end products with deterioration of periodontitis in type 2 diabetes patients. J Periodontol 2006; 77: 15-20.
111. Katz J, Bhattacharyya I, Farkhondeh-Kish F, Perez FM, Caudle RM, Heft MW. Expression of the receptor of advanced glycation end products in gingival tissues of type 2 diabetes patients with chronic periodontal disease: a study utilizing immunohistochemistry and RT-PCR. J Clin Periodontol 2005; 32: 40-44.
112. Goova MT, Li J, Kislinger T etal. Blockade of receptor for advanced glycation end-products restores effective wound healing in diabetic mice. Am J Pathol 2001; 159: 513-525.
113. Cortizo AM, Lettieri MG, Barrio DA, Mercer N, Etcheverry SB, McCarthy AD. Advanced glycation end-products (AGEs) induce concerted changes in the osteoblastic expression of their receptor RAGE and in the activation of extracellular signal-regulated kinases (ERK). Mol Cell Biochem 2003; 250: 1-10.
114. Esposito C, Gerlach H, Brett J, Stern D, Vlassara H. Endothelial receptor-mediated binding of glucose-modified albumin is associated with increased monolayer permeability and modulation of cell surface coagulant properties. J Exp Med 1989; 170: 1387-1407.
115. Vlassara H. The AGE-receptor in the pathogenesis of diabetic complications. Diabetes Metab Res Rev 2001; 17: 436-443.
116. Ding KH, Wang ZZ, Hamrick MW etal. Disordered osteoclast formation in RAGE-deficient mouse establishes an essential role for RAGE in diabetes related bone loss. Biochem Biophys Res Commun 2006; 340: 1091-1097.
117. Yoshida T, Flegler A, Kozlov A, Stern PH. Direct inhibitory and indirect stimulatory effects of RAGE ligand S100 on sRANKL-induced osteoclastogenesis. J Cell Biochem 2009; 107: 917-925.
118. Lalla E, Lamster IB, Feit M etal. Blockade of RAGE suppresses periodontitis-associated bone loss in diabetic mice. J Clin Invest 2000; 105: 1117-1124.
119. Newbrun E. Indices to measure gingival bleeding. J Periodontol 1996; 67: 555-561.
120. Karjalainen KM, Knuuttila ML. The onset of diabetes and poor metabolic control increases gingival bleeding in children and adolescents with insulin-dependent diabetes mellitus. J Clin Periodontol 1996; 23: 1060-1067.
121. Sastrowijoto SH, van der Velden U, van Steenbergen TJ etal. Improved metabolic control, clinical periodontal status and subgingival microbiology in insulin-dependent diabetes mellitus. A prospective study. J Clin Periodontol 1990; 17: 233-242.
122. Choi YH, McKeown RE, Mayer-Davis EJ, Liese AD, Song KB, Merchant AT. Association between periodontitis and impaired fasting glucose and diabetes. Diabetes Care 2011; 34: 381-386.
123. Demmer RT, Jacobs DRJ, Desvarieux M. Periodontal disease and incident type 2 diabetes: results from the First National Health and Nutrition Examination Survey and its epidemiologic follow-up study. Diabetes Care 2008; 31: 1373-1379.
124. Ide R, Hoshuyama T, Wilson D, Takahashi K, Higashi T. Periodontal disease and incident diabetes: a seven-year study. J Dent Res 2011; 90: 41-46.
125. Demmer RT, Desvarieux M, Holtfreter B etal. Periodontal status and A1C change: longitudinal results from the Study of Health in Pomerania (SHIP). Diabetes Care 2010; 33: 1037-1043.
126. Morita I, Inagaki K, Nakamura F etal. Relationship between periodontal status and levels of glycated hemoglobin. J Dent Res 2012; 91: 161-166.
127. Baelum V, Papapanou PN. CPITN and the epidemiology of periodontal disease. Community Dent Oral Epidermiol 1996; 24: 367-368.
128. Lalla E, Kunzel C, Burkett S, Cheng B, Lamster IB. Identification of unrecognized diabetes and pre-diabetes in a dental setting. J Dent Res 2011; 90: 855-860.
129. Thorstensson H. Medical status and complications in relation to periodontal disease experience in insulin-dependent diabetics. J Clin Periodontol 1996; 23: 194-202.
130. Saremi A, Nelson RG, Tulloch-Reid M etal. Periodontal disease and mortality in type 2 diabetes. Diabetes Care 2005; 28: 27-32.
131. Shultis WA, Weil EJ, Looker HC etal. Effect of periodontitis on overt nephropathy and end-stage renal disease in type 2 diabetes. Diabetes Care 2007; 30: 306-311.
132. Shlossman M, Knowler WC, Pettitt DJ, Genco RJ. Type 2 diabetes mellitus and periodontal disease. J Am Dent Assoc 1990; 121: 532-536.
133. Li Q, Chalmers J, Czernichow S etal. Oral disease and subsequent cardiovascular disease in people with type 2 diabetes: a prospective cohort study based on the action in diabetes and vascular disease: preterax and diamicron modified-release controlled evaluation (ADVANCE) trial. Diabetologia 2010; 53: 2320-2327.
134. Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation 2003; 107: 391-397.
135. Paraskevas S, Huizinga JD, Loos BG. A systematic review and meta-analyses on C-reactive protein in relation to periodontitis. J Clin Periodontol 2008; 35: 277-290.
136. Koro CE, Bowlin SJ, Bourgeois N, Fedder DO. Glycemic control from 1988 to 2000 among U.S. adults diagnosed with type 2 diabetes: a preliminary report. Diabetes Care 2004; 27: 17-20.
137. Stratton IM, Adler AI, Neil HAW etal. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321: 405-412.
138. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577-1589.
139. WHO. Use of glycated haemoglobin (HbA1c) for the diagnosis of diabetes mellitis 2011. WHO reference number: WHO/NMH/CHP/CPM/11.1.
140. D'Aiuto F, Parkar M, Andreou G etal. Periodontitis and systemic inflammation: control of the local infection is associated with a reduction in serum inflammatory markers. J Dent Res 2004; 83: 156-160.
141. Lopez NJ, Quintero A, Casanova PA, Ibieta CI, Baelum V, Lopez R. Effects of periodontal therapy on systemic markers of inflammation in patients with metabolic syndrome: a controlled clinical trial. J Periodontol 2012; 83: 267-278.
142. Collin H-L, Uusitupa M, Niskanen L etal. Periodontal findings in elderly patients with non-insulin dependent diabetes mellitus. J Periodontol 1998; 69: 962-966.
143. Christgau M, Palitzsch KD, Schmalz G, Kreiner U, Frenzel S. Healing response to non-surgical periodontal therapy in patients with diabetes mellitus: clinical, microbiological, and immunologic results. J Clin Periodontol 1998; 2: 112-124.
144. Grossi SG, Skrepcinski FB, DeCaro T etal. Treatment of periodontal disease in diabetics reduces glycated hemoglobin. J Periodontol 1997; 68: 713-719.
145. Aldridge JP, Lester V, Watts TL, Collins A, Viberti G, Wilson RF. Single-blind studies of the effects of improved periodontal health on metabolic control in type 1 diabetes mellitus. J Clin Periodontol 1995; 22: 271-275.
146. Miller LS, Manwell MA, Newbold D etal. The relationship between reduction in periodontal inflammation and diabetes control: a report of 9 cases. J Periodontol 1992; 63: 843-848.
147. Katagiri S, Nagasawa T, Kobayashi H etal. Improvement of glycemic control after periodontal treatment by resolving gingival inflammation in type 2 diabetic patients with periodontal disease. J Diabetes Investig 2012; 3: 402-409.
148. Lalla E, Papapanou PN. Diabetes mellitus and periodontitis: a tale of two common interrelated diseases. Nat Rev Endocrinol 2011; 7: 738-748.
149. Higgins J, Green S. Cochrane handbook for systematic reviews of interventions 5.2.1. The Cochrane Collaboration, 2011. Updated March 2011; Accessed 31 October 2012. Available from: http://www.cochrane-handbook.org
150. Hare MJL, Shaw JE, Zimmet PZ. Current controversies in the use of haemoglobin A1c. J Intern Med 2012; 271: 227-236.
151. Davidson MB, Schriger DL. Effect of age and race/ethnicity on HbA1c levels in people without known diabetes mellitus: implications for the diagnosis of diabetes. Diabetes Res Clin Pract 2010; 87: 415-421.
152. Jorgensen ME, Bjerregaard P, Borch-Johnsen K, Witte D. New diagnostic criteria for diabetes: is the change from glucose to HbA1c possible in all populations? J Clin Endocrinol Metab 2010; 95: E333-336.
153. Koromantzos PA, Makrilakis K, Dereka X, Katsilambros N, Vrotsos IA, Madianos PN. A randomized, controlled trial on the effect of non-surgical periodontal therapy in patients with type 2 diabetes. Part I: effect on periodontal status and glycaemic control. J Clin Periodontol 2011; 38: 142-147.
154. Moeintaghavi A, Arab HR, Bozorgnia Y, Kianoush K, Alizadeh M. Non-surgical periodontal therapy affects metabolic control in diabetics: a randomized controlled clinical trial. Aust Dent J 2012; 57: 31-37.
155. Chen L, Luo G, Xuan D etal. Effects of non-surgical periodontal treatment on clinical response, serum inflammatory parameters, and metabolic control in patients with type 2 diabetes: a randomized study. J Periodontol 2012; 83: 435-443.
156. Lin SJ, Tu YK, Tsai SC, Lai SM, Lu HK. Non-surgical periodontal therapy with and without subgingival minocycline administration in patients with poorly controlled type II diabetes: a randomized controlled clinical trial. Clin Oral Investig 2012; 16: 599-609.
157. Auyeung L, Wang P-W, Lin R-T etal. Evaluation of periodontal status and effectiveness of non-surgical treatment in patients with type 2 diabetes mellitus in Taiwan for a 1-year period. J Periodontol 2011; 83: 621-628.
158. Darre L, Vergnes JN, Gourdy P, Sixou M. Efficacy of periodontal treatment on glycaemic control in diabetic patients: a meta-analysis of interventional studies. Diabetes Metab 2008; 34: 497-506.
159. Teeuw WJ, Gerdes VEA, Loos BG. Effect of periodontal treatment on glycemic control of diabetic patients: a systematic review and meta-analysis. Diabetes Care 2010; 33: 421-427.
160. Janket SJ, Wightman A, Baird AE, Van Dyke TE, Jones JA. Does periodontal treatment improve glycemic control in diabetic patients? A meta-analysis of intervention studies. J Dent Res 2005; 12: 1154-1159.
161. Sgolastra F, Severino M, Pietropaoli D, Gatto R, Monaco A. Effectiveness of periodontal treatment to improve metabolic control in patients with chronic periodontitis and type 2 diabetes: a meta-analysis of randomized clinical trials. J Periodontol 2013; 84: 958-973.
162. Preshaw PM, Alba AL, Herrera D etal. Periodontitis and diabetes: a two-way relationship. Diabetologia 2012; 55: 21-31.
163. Kiran M, Arpak N, Unsal E, Erdogan MF. The effect of improved periodontal health on metabolic control in type 2 diabetes mellitus. J Clin Periodontol 2005; 32: 266-272.
164. Jones JA, Miller DR, Wehler CJ etal. Does periodontal care improve glycemic control? The Department of Veterans Affairs Dental Diabetes Study. J Clin Periodontol 2007; 34: 46-52.
165. Yun F, Firkova EI, Jun-Qi L, Xun H. Effect of non-surgical periodontal therapy on patients with type 2 diabetes mellitus. Folia Med (Plovdiv) 2007; 49: 32-36.
166. Singh S, Kumar V, Kumar S, Subbappa A. The effect of periodontal therapy on the improvement of glycemic control in patients with type 2 diabetes mellitus: a randomized controlled clinical trial. Int J Diabetes Dev Ctries 2008; 28: 38-44.